Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive bandage zaps skin cancer in early trial

NCT ID NCT04480645

Disease control Sponsor: CivaTech Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early pilot study tested a new radioactive bandage called CivaDerm on 10 people with common skin cancers (basal cell or squamous cell carcinoma). The bandage delivers radiation directly to the skin surface, aiming to destroy cancer cells while sparing healthy tissue. The study checked for skin side effects and how much radiation reached the tumor.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radioactive bandage (palladium-103)
What this could lead to
If it works, this could offer a simpler, targeted radiation treatment for common skin cancers without surgery.
What could go wrong
This is a very early pilot study with only 10 people. It is not yet proven to be safe or effective, and radiation can cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

10 people

The number who actually took part.

Started

May 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * subject signed informed consent * Confirmed superficial or nodular basal cell or squamous cell carcinoma * Biopsy proven on chest, stomach, back, arms, legs, feet (trunk and extremities) * \>5 mm of residual tumor * tumors \< 3 cm * Capable of complying with Patient Release Instructions Exclusion Criteria: * Is unable or unwilling to comply with the protocol requirements * Pregnant or breast feeding * Metastases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin neoplasm skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma Squamous cell carcinoma of the skin

Contacts and locations

Locations

  • CivaDerm Oncology PLLC

    Morrisville, North Carolina, 27560, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.